TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06565104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidimensional Sleep Health Sessions
Description: The two sleep health educational sessions will include didactic content on defining sleep health, reviewing sleep recommendations, outlining the role of sleep in preserving cardiometabolic health, and correcting unhelpful sleep-related beliefs and debunking myths. Participants will learn to maximize the benefits of self-monitoring using a Fitbit and will receive a sleep mask, ear plugs, a blue light blocker, and an indoor air purifier to improve their sleep environment.
Study: NCT06608680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iTBS
Description: Excitatory stimulation of supramarginal gyrus

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cTBS
Description: Inhibitory stimulation to supramarginal gyrus

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sham Stimulation
Description: Sham stimulation of supramarginal gyrus

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sham Stimulation
Description: Sham stimulation of supramarginal gyrus
Study: NCT06661473

Intervention type: DEVICE
Group type: OTHER
Intervention: Avance Solo Negative Pressure Wound Therapy
Description: Avance Solo NPWT 7-14 days after high-risk revision TKA or THA.
Study: NCT06661525

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Free Flap NIRS
Description: Monitoring of tissue oxygenation after Free Tissue Transfer (FTT) surgeries.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free Flap NIRS
Description: Monitoring of tissue oxygenation after Free Tissue Transfer (FTT) surgeries.
Study: NCT06660771

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional orthodontic treatment
Description: The patients were treated with Twin block and Herbst functional appliances. Alginate impressions and a protrusive wax bite were taken for the construction of each appliance. Each device was fitted and then reviewed 4-6 weeks later. First group was treated with Twin block which was manufactured basically according to the original design described by Clark. The overjet was measured from the patients in centric relationship and maximum protrusion position, and construction bite was recorded with 70% of the total advancement capacity of the mandible and 2-4 mm above the freeway space vertically. Overjet measurements were made at each session and active treatment was terminated when a normal overjet in the retracted position was recorded.~Second group was treated with the stainless-steel crown Herbst appliance, included crowned maxillary first molars and mandibular first premolars. The construction bite was recorded with the mandible forward by edge-to-edge incisor position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional orthodontic treatment
Description: The patients were treated with Twin block and Herbst functional appliances. Alginate impressions and a protrusive wax bite were taken for the construction of each appliance. Each device was fitted and then reviewed 4-6 weeks later. First group was treated with Twin block which was manufactured basically according to the original design described by Clark. The overjet was measured from the patients in centric relationship and maximum protrusion position, and construction bite was recorded with 70% of the total advancement capacity of the mandible and 2-4 mm above the freeway space vertically. Overjet measurements were made at each session and active treatment was terminated when a normal overjet in the retracted position was recorded.~Second group was treated with the stainless-steel crown Herbst appliance, included crowned maxillary first molars and mandibular first premolars. The construction bite was recorded with the mandible forward by edge-to-edge incisor position.
Study: NCT06565104

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Diet Sessions
Description: The two diet sessions include an overview of nutrition basics, examples of healthy dietary patterns and cooking methods to increase consumption of plant-based foods such as fruits, vegetables, and whole grains, promote choosing more lean proteins such as fish, and reduce intakes of red and processed meats, sugary foods, and sugar-sweetened beverages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Diet Sessions
Description: The two diet sessions include an overview of nutrition basics, examples of healthy dietary patterns and cooking methods to increase consumption of plant-based foods such as fruits, vegetables, and whole grains, promote choosing more lean proteins such as fish, and reduce intakes of red and processed meats, sugary foods, and sugar-sweetened beverages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Sessions
Description: The two physical activity sessions provide an overview of the physical activity guidelines and include 30-60 minutes of exercise and a healthy living community resource mapping exercise. These sessions also address achieving and maintaining a healthy body weight.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Sessions
Description: The two physical activity sessions provide an overview of the physical activity guidelines and include 30-60 minutes of exercise and a healthy living community resource mapping exercise. These sessions also address achieving and maintaining a healthy body weight.
Study: NCT04957992

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Infant Formula
Description: Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Toddler Drink
Description: \~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Toddler Drink
Description: \~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age

Intervention type: OTHER
Group type: OTHER
Intervention: Human Milk
Description: Ad libitum or as instructed by HCP

Intervention type: OTHER
Group type: OTHER
Intervention: Human Milk Supplemental Formula
Description: Ad libitum if consuming supplemented formula; feeding period up to 12 months of age

Intervention type: OTHER
Group type: OTHER
Intervention: Human Milk Toddler Drink
Description: \~16 fl oz per day if providing supplemental nutrition other than HM; feeding period from 12 to 24 months of age
Study: NCT05006547

Intervention type: OTHER
Intervention: Electromyograph Biofeedback training of the peroneal muscle
Description: The exercise will be performed with the subject sitting in front of a computer monitor, on an elevated chair, and his feet will be in the air. The examiner will ask the subject to perform a maximum contraction of the paronal muscles, in an open kinematic chain. After reference, the subject will begin a five-minute practice. The practice will be divided into rounds of: eight seconds of muscle work and 15 seconds rest.

Intervention type: OTHER
Intervention: Electromyograph Biofeedback training of the peroneal muscle
Description: The exercise will be performed with the subject sitting in front of a computer monitor, on an elevated chair, and his feet will be in the air. The examiner will ask the subject to perform a maximum contraction of the paronal muscles, in an open kinematic chain. After reference, the subject will begin a five-minute practice. The practice will be divided into rounds of: eight seconds of muscle work and 15 seconds rest.
Study: NCT05287256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Delta-8-THC Cannabis
Description: Delta-8-THC cannabis will be orally self-administered by study participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Delta-8-THC Cannabis
Description: Delta-8-THC cannabis will be orally self-administered by study participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Delta-8-THC Cannabis
Description: Delta-8-THC cannabis will be orally self-administered by study participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Delta-9-THC Cannabis
Description: Delta-9-THC cannabis will be orally self-administered by study participants

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Placebo will be orally self-administered by study participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized Delta-8-THC Cannabis
Description: Delta-8-THC cannabis will be self-administered by study participants using a vaporizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized Delta-8-THC Cannabis
Description: Delta-8-THC cannabis will be self-administered by study participants using a vaporizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized Delta-8-THC Cannabis
Description: Delta-8-THC cannabis will be self-administered by study participants using a vaporizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized Delta-9-THC Cannabis
Description: Delta-9-THC cannabis will be self-administered by study participants using a vaporizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaporized Placebo
Description: Placebo will be self-administered by study participants using a vaporizer
Study: NCT05918406

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nasal Guide
Description: Use of Nasal Guide with administration of Tyrvaya (varenicline solution 0.03 mg) BID
Study: NCT05893823

Intervention type: DIAGNOSTIC_TEST
Intervention: Pelvis CT scan
Description: Post-THA hip pelvis CT scan execution for pain, noise or THA planning for the controlateral hip, with identification of acetabular cup protrusion. Comparation of cases and controls to identify radiological factors that could potentially lead to symptomatic psoas impingement prediction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pelvis CT scan
Description: Post-THA hip pelvis CT scan execution for pain, noise or THA planning for the controlateral hip, with identification of acetabular cup protrusion. Comparation of cases and controls to identify radiological factors that could potentially lead to symptomatic psoas impingement prediction.
Study: NCT06056258

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VL-NL-02
Description: Two capsules to be taken 45±10 mins before sleep (after dinner) for 21 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules to be taken 45±10 mins before sleep (after dinner) for 21 days
Study: NCT05868421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Person Coaching Call
Description: Support person participants assigned to the intervention group will additionally receive a 1-call coaching session about 15-25 minutes in duration on how to support their Veteran smoker. The session will be delivered by research staff by phone or video call. Support persons in the intervention group and the control/no intervention group will receive existing written material resources on support strategies to stop smoking, and resources on how to stop smoking by postal mail or email.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SP written materials
Description: Written materials covering tips on effective supportive strategies for smoking cessation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SP written materials
Description: Written materials covering tips on effective supportive strategies for smoking cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Smoking Cessation Materials
Description: Written materials on resource and referral information for VHA and non-VHA EBCT options

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Smoking Cessation Materials
Description: Written materials on resource and referral information for VHA and non-VHA EBCT options
Study: NCT05391230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Permethrin-treated lesu
Description: 0.5% permethrin soaked baby wraps (lesus)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Untreated lesu
Description: Water soaked baby wraps (lesus)
Study: NCT04417166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 50 mg powder for concentrate for solution for infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved Field Radiation Therapy
Description: 50-54 Gy Involved Field Radiation Therapy (IFRT) as proposed by the International Lymphoma Radiation Oncology Group (ILROG) guidelines. 50 Gy is recommended in patients without primary tumor invasiveness (invasion to adjacent tissue and/or organs), 54 Gy in locally advanced cases (invasion to adjacent tissue and/or organs) or with other risk factors (age \> 60 years, stage II, elevated serum LDH levels).~Intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) are recommended but not mandatory; 3-dimensional conformal RT (3D-CRT) is allowed.
Study: NCT06653036

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dural puncture epidural
Description: The Dural puncture epidural technique is done by assessing the epidural space using the Touhy needle and puncturing the dura matter with a finer needle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Epidural Technique
Description: The Standard Epidural Technique is usually performed by identifying the epidural space using the loss of resistance technique and threading the epidural catheter in the epidural space for administration of analgesic drugs.
Study: NCT05562557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement
Description: To encourage intrinsic motivation to engage in fatherhood activities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HERO Dads Fatherhood Program
Description: Fatherhood engagement curriculum to increase awareness, knowledge, and skills for parenting and co-parenting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: To reinforce healthy behaviors, including attendance at services
Study: NCT05339490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progenitor Biological Bandages
Description: The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, PBB will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1. Old PBB will be replaced by new ones according to the local procedure.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jelonet
Description: The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, Jelonet, as standard bandages, will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality.
Study: NCT06511674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-emotional and pain assessments
Description: Data collection on cognitive-emotional and pain parameters using questionnaires.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-emotional and pain assessments
Description: Data collection on cognitive-emotional and pain parameters using questionnaires.
Study: NCT05372731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver
Description: RM after BAL
Study: NCT05472675

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botulinum toxin and bupivacain
Description: Botulinum toxin A AND bupivacain( local anesthetic)
Study: NCT04074018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-rehabilitation program
Description: facial self-rehabilitation for a duration of 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation program
Description: Conventional facial rehabilitation for a duration of 6 months
Study: NCT04809818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT3001 drug product
Description: Multiple doses of LT3001 drug product administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT3001 drug product
Description: Multiple doses of LT3001 drug product administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT3001 drug product
Description: Multiple doses of LT3001 drug product administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT3001 drug product
Description: Multiple doses of LT3001 drug product administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT3001 drug product
Description: Multiple doses of LT3001 drug product administered by intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple doses of Placebo administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Loading and maintenance doses of Aspirin administered by oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Loading and maintenance doses of Clopidogrel administered by oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Multiple doses of Apixaban administered by oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Multiple doses of Dabigatran administered by oral
Study: NCT05645068

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography Angiography
Description: Optical Coherence Tomography Angiography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multidisciplinary care program
Description: multidisciplinary care program including sports activity
Study: NCT05562557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Management
Description: Referrals to treatment, social services, and employment services
Study: NCT05016310

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dose Vitamin D
Description: High dose vitamin D: Subjects will receive 50,000 IU vitamin D2 weekly x 16 weeks followed by 4,000 IU of vitamin D3 daily with a goal 25(OH)D level of ≥45 but ≤80 ng/mL.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Vitamin D
Description: Standard of Care Vitamin D: Vitamin D will be supplemented to 25(OH)D levels, with a goal 25(OH)D level of \>30 ng/mL according to Endocrine Society Practice Guidelines.
Study: NCT05964907

Intervention type: DEVICE
Group type: OTHER
Intervention: Light Source B: Visible Light solar simulator (VL + UVA1)
Description: Patients will be radiated with light source B (Visible light solar simulator)

Intervention type: DEVICE
Group type: OTHER
Intervention: Light Source A: Visible Light solar simulator closer match to sunlight (VL +UVA1)
Description: Patients will be radiated with light source A (Visible light solar simulator closer match to sunlight)
Study: NCT05746741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth solution
Description: Video conferencing
Study: NCT05860504

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: All patients in the study will be examined with echocardiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: All patients in the study will be examined with echocardiography
Study: NCT06165445

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm) or via more than two but smaller round electrodes over the target regions.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm) or via more than two but smaller round electrodes over the target regions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: multichannel transcranial direct current stimulation (tDCS)
Description: In multichannel tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through more than two and smaller round electrodes over the target regions.
Study: NCT04354129

Intervention type: DRUG
Intervention: Cutaquig®
Description: Immunoglobulin replacement therapy with subcutaneous injections of Cutaquig® 165 mg/mL at home.
Study: NCT06542484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant Citrate
Description: An additional treatment of gefapixiant will be performed for 12 weeks.
Study: NCT06648629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: ACT is a trans-diagnostic treatment that targets experiential avoidance as an underlying factor common to mental and behavioral health problems. Mindfulness skills and values-guided behavioral action plans are used to decrease experiential avoidance and impact a broad array of psychological symptoms via improved psychological acceptance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Alcohol Intervention
Description: The Brief Alcohol Intervention (BI) is a standard intervention for reducing alcohol use in PWH. The BI includes the creation of a drinking agreement, self-monitoring via drinking diary cards, discussion of risky moods/situation, and strategies for managing these moods/situations.